Q-omics provides the consensus-scored ITLN1 profile across patient tissues and cancer cell-line models. ITLN1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ITLN1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, ITLN1 RNA expression shows 11,071 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LUAD, and TGCT as cancer lineages where ITLN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ITLN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ITLN1 survival associations across molecular data types. ITLN1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ITLN1 RNA expression–survival associations across cancer types. High ITLN1 expression shows unfavorable associations in THYM and KIRC, but favorable associations in MESO, COAD, UVM and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ITLN1 RNA expression.
This table summarizes ITLN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ITLN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ITLN1 shows lower tumor expression in LUAD, KIRP, KIRC, KICH, COAD and LIHC. The LUAD box plot shows higher ITLN1 RNA expression in normal versus tumor tissue (log2 FC = −5.640, t-test p < 0.001).
This table shows molecular features associated with ITLN1 in patient tissues and cancer cell lines. In patient samples, ITLN1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ITLN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
